KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Other Working Capital Changes (2016 - 2025)

Pfizer (PFE) has disclosed Other Working Capital Changes for 17 consecutive years, with -$8.2 billion as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes changed N/A to -$8.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.3 billion through Dec 2025, changed N/A year-over-year, with the annual reading at -$1.3 billion for FY2025, 61.86% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was -$8.2 billion at Pfizer, down from $36.0 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was $8.1 billion in Q4 2022, with the low at -$10.9 billion in Q4 2021.
  • Average Other Working Capital Changes over 5 years is $520.3 million, with a median of $1.9 billion recorded in 2025.
  • The sharpest move saw Other Working Capital Changes tumbled 1095.01% in 2021, then surged 654.38% in 2023.
  • Over 5 years, Other Working Capital Changes stood at -$10.9 billion in 2021, then skyrocketed by 174.36% to $8.1 billion in 2022, then tumbled by 223.24% to -$10.0 billion in 2023, then surged by 160.17% to $6.0 billion in 2024, then plummeted by 237.4% to -$8.2 billion in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at -$8.2 billion, $36.0 million, and $5.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.